According to the recent study by Astute Analytica, the U.S. liquid biopsy market is witnessing a rise a revenue from US$ 3,786.2 million in 2023 to surpass a market valuation of US$ 12,004.9 million by 2032.
According to the recent study by Astute Analytica, the U.S. liquid biopsy market is witnessing a rise a revenue from US$ 3,786.2 million in 2023 to surpass a market valuation of US$ 12,004.9 million by 2032. The market is projected to grow at a CAGR of 13.68% during the forecast period from 2024 to 2032.
Get Free Sample Copy of Report@ https://www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market
Recently, there has been substantial growth in the U.S. liquid biopsy market due to technological advancements and a rise in the occurrence of cancer and chronic illnesses. This has led to increased interest in and use of liquid biopsies. These non-invasive examinations have generated significant excitement because they can consistently offer information about a patient’s cancer condition, providing important direction for treatment plans. Given its ability to supply details about the cancer stage and spread, track treatment effects, detect potential recurrence early, and identify reasons for treatment resistance, there is a rising need for liquid biopsy in the U.S.
Cancer remains the second leading cause of death in the United States, with over 1.8 million new cancer diagnoses and more than 0.6 million cancer deaths each year. Early cancer diagnosis is crucial for increasing survival rates and reducing care costs. Therefore, there is a significant need for minimally invasive, early detection methods that can provide a molecular diagnosis to allow timely patient stratification to appropriate therapies.
Over the past two decades, the field of liquid biopsy has emerged, involving the study of a sample of biofluid (blood, cerebrospinal fluid, urine, saliva, amniotic fluid, ascitic fluid) to examine cancer-derived circulating tumor cells (CTCs), circulating nucleic acids including cell-free DNA (cfDNA), cell-free RNA including mRNA, long non-coding RNAs (lncRNAs) and microRNA (miRNA), extracellular vesicles (EVs), tumor-educated platelets, proteins, and metabolites.
In line with this, the National Cancer Institute (NCI) Division of Cancer Prevention has initiated and sponsored an academic/industrial partnership program designed to advance and validate liquid biopsy technologies specifically targeted for early-stage cancer detection. Liquid biopsy has the potential to offer advantages over tissue biopsies and imaging approaches, providing cost and morbidity reductions when compared with surgical excision of tissues and costly computed tomography (CT), positron emission, and magnetic resonance (MRI) studies.
Cost Effectiveness of Liquid Biopsy in U.S.
The cost of liquid biopsy for second-line colorectal cancer screening was found to be not cost-effective and would need to be reduced by 66% to increase uptake among the general population, according to data in JAMA Network Open. This economic evaluation estimates the cost-effectiveness of liquid biopsy for colorectal screening in the U.S. While there has been increasing investment in liquid biopsy for its potential to detect early cancer, it remains unclear whether it is a cost-effective colorectal cancer screening strategy in the U.S.
According to the results of JAMA Network, the cost of liquid biopsy would have to be reduced by 66%—from $949 to $324—to become cost-effective, and liquid biopsy would have to drop to $56.16 to be cost-effective compared to no screening in the current simulated model. In 2022, the average price of a liquid biopsy test was around $2,800—almost four times as much as a traditional tissue biopsy test, deterring many patients and healthcare providers from adopting liquid biopsies.
In this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was found to be a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. Liquid biopsy tests for colorectal cancer screening may become cost-effective if their cost is substantially lowered.
Overall, the cost-effectiveness of liquid biopsy for colorectal cancer screening in the U.S. remains a topic of ongoing evaluation and discussion, with the current cost of liquid biopsy posing a significant barrier to its widespread adoption as a screening strategy.
Ask here for customization study@ https://www.astuteanalytica.com/ask-for-customization/united-states-liquid-biopsy-market
Blood vs. Tissue: The Shifting Landscape of Diagnostic Sampling
Certain fragments of DNA released by tumors into the bloodstream can be used for non-invasive screening of early-stage cancers, monitoring treatment responses, and understanding therapy resistance. Tissue biopsies, often used for tumor analysis, can be challenging due to their cost, pain, and potential risk to the patient. In contrast, utilizing blood samples for liquid biopsy has emerged as a promising alternative, with over 69% of revenues in 2023 derived from this method.
The use of blood samples for liquid biopsy is expected to experience robust growth, with an estimated strong compound annual growth rate (CAGR) of 14.10% in the coming years. This breakthrough is primarily centered around the simplicity of a blood draw, which offers advantages over invasive surgical procedures required for tissue biopsies.
Frequent blood draws facilitated by liquid biopsy technology enable continuous monitoring of cancer progression over time. This ongoing analysis, supported by simple blood draws, allows for more frequent and non-invasive monitoring compared to the limitations of tissue biopsies, which are not conducive to repeated procedures due to their invasiveness.
Highly Fragmented Market: Established Companies and Startups Struggling for Space
The fluid biopsy market is characterized by significant fragmentation and the presence of a few major players. As of 2023, the U.S. market has become highly competitive, with both established companies and new startups vying for dominance.
In 2022, Guardant Health held a substantial market share and is known for commercializing advanced cancer treatments through its patented digital sequencing technology, particularly Guardant360, which is used for early cancer identification and throughout cancer therapy for monitoring recurrent and residual disease.
The company has also introduced Guardant Infinity, a blood-based technology that combines epigenomic and genomic profiling with artificial intelligence to provide a multidimensional view of a patient’s cancer.
Top Players in the U.S. Liquid Biopsy Market
- Biocept, Inc.
- Illumina, Inc.
- Myriad Genetics, Inc.
- QIAGEN
- Thermo Fisher Scientific, Inc.
- Guardant Health
- F. Hoffmann-La Roche Ltd
- ANGLE plc
- BIODESIX
- NeoGenomics Laboratories, Inc.
- Other Major Players
Market Segmentation Overview
By Technology
- Multi Gene Parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
By Product
- Blood Sample Based
- Others
By Biomarker
- Circulating Nucleic Acids
- CTC
- Exosomes/Microvesicles
- Circulating Proteins
Immediate Delivery Available | Buy This Premium Research
https://www.astuteanalytica.com/industry-report/united-states-liquid-biopsy-market?buy_now=true&license_type=single
Contact us:
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: sales@astuteanalytica.com
Website: https://www.astuteanalytica.com/